OncoPharm
John Bossaer
Add to My Podcasts
Episodes
About
Reviews
Promote
Tepotinib
15 minutes
Posted Feb 4, 2021 at 3:38 pm.
0:00
15:30
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
In light of teptinib's recent FDA-approval for exon-14 skipping MET altered metastatic NSLCC, we compare tepotinib to its predecessor in this space - capmatinib.
Previous
Updates on mRCC and COVID-19 Vaccination
Next
Umbralisib
← See all 273 episodes of OncoPharm